Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome

Bibliography

• DONN SM, SINHA SK: Respiratory distress syndrome. In: Manua] of Neonatal Respiratory Care. SK Sinha, SM Donn (Eds.), Futura Publishing Co., Armonk, NY, USA (2000):260–265.
   Google Scholar
• LACAZE-MASMONTEIL T: Exogenous surfactant therapy: newer developments. NeonatoL (2003) 8:433–440.
   Google Scholar
• •Overview of surfactant replacement therapy.
   Google Scholar
• CURSTEDT T, JORNVALL H, ROBERTSON B et al.: Two hydrophobic, low-molecular mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur. Biochein. (1987) 168:255–262.
   PubMedGoogle Scholar
• BERNHARD W, MOTTAGHIAN J, GEBERT A, RAU GA, VON DER HARDT H, POETS CF: Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am. .1 Respir. Crit. Care Med. (2000) 162:1524–1533.
   Google Scholar
• CLARK JC, WERT SE, BACHURSKI CJ et al.: Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc. Natl. Acad. Sci. USA (1995) 92:7794–7798.
   PubMed Web of Science ®Google Scholar
• NOGEE LM, DE MELLO DE, DEHNER LP et al.: Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl. Med. (1993) 328:406–410.
   PubMed Web of Science ®Google Scholar
• MERRITT TA, STRAYER DS, HALLMAN M et al.: Immunologic consequences of exogenous surfactant administration. Seinin. Perinatol (1988) 12:221–230.
   PubMed Web of Science ®Google Scholar
• STRAYER DS, HALLMAN M, MERRITT TA: Immunogenicity of surfactant. II: porcine and bovine surfactants. Clia Exp. Iminunol (1991) 83:41–46.
   PubMed Web of Science ®Google Scholar
• MOYA F, HOFFMAN D, ZHAO B et al: Platelet activating factor in surfactant preparations. Lancet (1993) 341:858–860.
   PubMed Web of Science ®Google Scholar
• BRUNI R: Focus on proteins, surfaces. Am. Physiol Lung Cell. Mol. PhysioL (2002) 283:L894–L896.
   PubMed Web of Science ®Google Scholar
• AINSWORTH SB, MILLIGAN DW: Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review Am. J. Respir. Med. (2002) 1:417–433.
   Google Scholar
• COCHRANE CG, REVAK SD: Protein-phospholipid interactions in pulmonary surfactant. The Parker B Francis Lectureship. Chest (1994) 105\(Suppl. 3):575–625.
   Google Scholar
• COCHRANE CG, REVAK SD: Pulmonary surfactant protein B (SP-B): structure-function relationships. Science (1991) 254:566–568.
   PubMed Web of Science ®Google Scholar
• ••Description of lucinactant and sinapultide.
   Google Scholar
• MANALO E, MERRITT TA, KHEITER A et al: Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4. Pediatr. Res. (1996) 39:947–952.
   PubMed Web of Science ®Google Scholar
• ANDERSSON S, KHEITER A, MERRITT TA: Oxidative inactivation of surfactants. Lung (1999) 177:179–189.
   PubMed Web of Science ®Google Scholar
• NUTT M, PATEL N, RAIRKAR M et al:Comparison of the novel lung surfactant Surfaxin (lucinactant) with currently available commercial products. Pediatr. Res. (2004) 55:514A.
   PubMed Web of Science ®Google Scholar
• REVAK SD, MERRITT TA, COCHRANE CG: In: Investigator Brochure. Surfaxin (lucinactant), Discovery Laboratories, Inc., (2003) (Data on Me).
   Google Scholar
• DISCOVERY LABORATORIES: In: Investigator Brochure. Surfaxin (lucinactant), Discovery Laboratories, Inc. (2003) (Data on file).
   Google Scholar
• ROMERO EJ, MOYA FR, TUVIM MJ, ALCORN JL: Interaction of an artificial surfactant in human pulmonary epithelial cells. Pediatr. Pulmonol (2005) 39(2):167–177.
   PubMed Web of Science ®Google Scholar
• COCHRANE CG, REVAK SD, MERRITT TA et al.: The efficacy and safety of KL4-SurIactant in preterm infants with respiratory distress syndrome. Am. J. Respir. Grit. Care Med. (1996) 153:404–410.
   PubMed Web of Science ®Google Scholar
• •Phase I clinical trial of lucinactant for RDS.
   Google Scholar
• MOYA F, GADZINOWSKI J, BANCALARI E et al: Superiority of a novel surfactant, Surfaxin (lucinactant) over Exosurf in preventing respiratory distress syndrome in very preterm infants: a pivotal, multinational, randomized trial. Pediatrics (2005) (In Press).
   Google Scholar
• ••Phase III pivotal trial of lucinactant forRDS.
   Google Scholar
• SINHA S, LACAZE-MASMONTEIL T, VALLS I SOLER A et al: Randomized controlled trial of a new generation surfactant, Surfaxin (lucinactant), versus poractant alfa (Curosurf) for the prevention and treatment of respiratory distress syndrome in very preterm infants. Pediatrics (2005) (In Press).
   Google Scholar
• ••Phase III pivotal trial of lucinactant forRDS.
   Google Scholar
• Surfactant replacement therapy for severeneonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group. Pediatrics (1988) 82:683–691.
   PubMedGoogle Scholar
• MOYA F, SINHA S, GADZINOWSKI J et al.: Comparison of all-cause mortality between the novel surfactant Surfaxin (lucinactant) and the animal-derived surfactants Survanta (Beractant) and Curosurf (poractant alfa). Pediatr. Res. (2005) (In Press).
   Google Scholar
• SPRAGG RG, LEWIS JF, WALMATH HD et al.: Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl. Med. (2004) 351:884–892.
   PubMed Web of Science ®Google Scholar
• HERTING E, RAUPRICH P, STICHTENOTH G et al: Resistance of different surfactant preparations to inactivation by meconium. Pediatric Res. (2001) 50:44–49.
   PubMed Web of Science ®Google Scholar
• WISWELL TE, KNIGHT GR, FINER NN et al: A multicenter, randomized, controlled trial comparing Surfaxin (lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics (2002) 109:1167–1168.
   PubMed Web of Science ®Google Scholar
• •Pilot trial of lucinactant for MAS.
   Google Scholar